CRB Inverbío

Biocross, S.L., a biotechnology company, develops blood tests for the diagnosis of Alzheimer’s diseases to neurologists.

Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine and cell therapies. The technology used by our equipment is unique and is protected by international patents.

Iden biotechnology is a scientific company, whose main activity is the generation, transfer, exploitation, and marketing of biotechnological knowledge. They are a technology transfer company matching market demands with biotechnology research developments from universities and technology centers. Their main target is to increase the transfer of quality technology from academia to industry.

Mecwins develops technology for nanomechanical sensing and uses its technology to produce sensitive immunoassays for oncology, cardiovascular disease, and infectious diseases. They improve the healthcare of those sections of the population who are particularly at risk.

Nuubo is a Spanish medical device company that develops wireless, wearable technologies to monitor physiological parameters. To do so, Nuubo has a platform known as nECG DYNAMIC PLATFORM, which makes it easier to perform and read an electrocardiogram remotely. Specifically, the system patented by Nuubo is made up of three elements: a biomedical garment that allows the electrocardiogram signal to be captured without interfering with the patient’s daily activity; a device that continuously records the information captured by the garment and which also allows the data to be sent wirelessly and in real time for processing; and analysis and visualization software that, using artificial intelligence algorithms, can interpret all of the information transmitted by the wireless device. The devices designed by Nuubo allow patients’ hearts to be monitored for longer periods of time and without feeling uncomfortable or intrusive. The company is headquartered in Madrid, Spain.

Ray Techniques Ltd. is engaged in the fabrication of nano-diamonds (ND) and ND compounds by an innovative technology.

Amadix is focused on developing and commercializing innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company's flagship product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis, aimed at reducing the high mortality rate associated with colon cancer. Amadix's approach emphasizes early detection, allowing for timely treatment while avoiding the complications of invasive procedures like tumor biopsies. The team comprises industry veterans with extensive expertise in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by independent board members who provide strategic guidance in commercialization and business development, particularly in Europe and the United States. Amadix's products undergo rigorous analytical validation and clinical studies before being introduced to the global market.

HIC’s foundational mission is “the identification of health problems that may benefit from a genetic diagnosis, and the development and provision of genetic testing services for those conditions”. Since the beginning of the company, our main differential value is the combination of Knowledge Management tools with an expert dedicated multidisciplinary team, which allows us to provide a unique level of interpretation for the best genotyping. Currently HIC is specialized in high quality sequencing services and in the interpretation of genetic tests, providing clinicians with the tool to offer personalized medical care. HIC is the European leader on genetic diagnosis of inherited cardiovascular diseases and constantly extending its scope to other diseases: dyslipidemias, skeletal myopathies and most recently, cancer.

Chosen as one of Spain’s top 5 biotech investment opportunities, TCD is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs. Established in 2005 and with one product, TCD-717, already in clinical trials the Company is positioning itself as Spain’s Partner of Choice for Oncology drug discovery and development opportunities. TCD’s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug development while significantly lowering risks and costs.

Chosen as one of Spain’s top 5 biotech investment opportunities, TCD is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs. Established in 2005 and with one product, TCD-717, already in clinical trials the Company is positioning itself as Spain’s Partner of Choice for Oncology drug discovery and development opportunities. TCD’s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug development while significantly lowering risks and costs.